Cargando…
Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria
Introduction: 5-Aminolevulinic acid dehydratase (ALAD) porphyria (ADP) is an autosomal recessive disease characterized by a profound deficiency in ALAD, the second enzyme in the heme biosynthetic pathway, and acute neurovisceral attacks with abdominal pain and peripheral neuropathy. Hemin infusions...
Autores principales: | Graff, Erica, Anderson, Karl E., Levy, Cynthia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386060/ https://www.ncbi.nlm.nih.gov/pubmed/35991568 http://dx.doi.org/10.3389/fgene.2022.867856 |
Ejemplares similares
-
Acute intermittent porphyria, givosiran, and homocysteine
por: Fontanellas, Antonio, et al.
Publicado: (2021) -
PB2559: VARIEGATE PORPHYRIA CONFIRMED BY NGS AND TREATED WITH GIVOSIRAN - CASE PRESENTATION
por: Georgescu, Georgeta Daniela
Publicado: (2023) -
Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study
por: Ventura, Paolo, et al.
Publicado: (2021) -
ALAD Inhibition
by Porphobilinogen Rationalizes the
Accumulation of δ-Aminolevulinate in Acute Porphyrias
por: San Juan, Itxaso, et al.
Publicado: (2022) -
Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
por: Petrides, Petro E., et al.
Publicado: (2021)